Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2000
03/28/2000US6043343 Amino acid sequence; for diagnosis and prevention of cancer and tumors; anticarcinogenic/antitumor agents; for screening compounds which bind to polypeptide
03/28/2000US6043250 Treating or preventing inflammatory diseases
03/28/2000US6043249 The compounds have either a sulfhydryl moiety or are reducible disulfides; antifolates
03/28/2000US6043238 2-Aminobenzazapine derivatives
03/28/2000US6043235 11β-aryl-17, 17-spirothiolane-substituted steroids
03/28/2000US6043234 Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen
03/28/2000US6043226 3,6-ketal and enol ether macrolide antibiotics
03/28/2000US6043219 Broad spectrum chemotherapeutic peptide
03/28/2000US6043094 Therapeutic liposome composition and method
03/28/2000US6043056 Amino acid sequences; for diagnosis, treatment, and prevention of blood, karyotypic, and nervous system disorders
03/28/2000US6043054 Polynucleotides encoding a novel GABA BP polypeptide
03/28/2000US6043053 Wnt-3 polynucleotides
03/28/2000US6042846 Resistant to nuclease hydrolysis; efficiency
03/28/2000US6042829 Biotherapy of cancer by targeting TP-3/P80
03/28/2000US6042828 Humanized antibodies to ganglioside GM2
03/28/2000US6042827 Anti-idiotypic antibody induction of anti-tumor response
03/28/2000US6042826 Administering intrathecally or intralesionally a therapeutically effective amount of a fas-crosslinking component selected from an agonsit antihuman fas monoclonal antibody, anti-human fas bid fragments, or soluble fas-ligand
03/28/2000US6042822 Mixture of alpha-interferon-conjugate positional isomers comprises an alpha-interferon covalently conjugated to a non-antigenic alkyl terminated polyalkylene oxide at a histidine residue on alpha interferon
03/28/2000US6042603 Method for improved selectivity in photo-activation of molecular agents
03/28/2000CA2143000C Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
03/28/2000CA2014472C N-acyl derivatives of the ll-e33288 antitumor antibiotics
03/23/2000WO2000015825A1 Condensed plasmid-liposome complex for transfection
03/23/2000WO2000015820A1 Adenovirus vectors containing cell status-specific response elements and methods of use thereof
03/23/2000WO2000015806A1 Atp synthase subunit homolog
03/23/2000WO2000015794A1 Human cell junction pdz protein
03/23/2000WO2000015793A2 Human gpcr proteins
03/23/2000WO2000015792A2 Promotion or inhibition of angiogenesis and cardiovascularization
03/23/2000WO2000015788A2 Dna sequence encoding oncofetal ferritin protein
03/23/2000WO2000015787A1 Genes encoding for the human and murine death inducer-obliterator-1
03/23/2000WO2000015780A1 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
03/23/2000WO2000015773A2 Inhibition of oncogene transcription by synthetic polyamides
03/23/2000WO2000015770A2 Human serine/threonine protein kinases
03/23/2000WO2000015766A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
03/23/2000WO2000015666A2 Compositions and methods for the treatment of tumors
03/23/2000WO2000015665A2 A method of producing a functional immunoglobulin superfamily protein
03/23/2000WO2000015659A2 Stomach polypeptide zsig28
03/23/2000WO2000015657A1 Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and 53
03/23/2000WO2000015655A1 Process for producing peptides from biological fluids and peptides obtainable by said process
03/23/2000WO2000015641A1 Compounds alkylating specific base sequence of dna and method for synthesizing the same
03/23/2000WO2000015639A1 Carboline derivatives as cgmp phosphodiesterase inhibitors
03/23/2000WO2000015614A1 Novel compounds
03/23/2000WO2000015609A1 Azetidine derivatives, preparation and medicines containing them
03/23/2000WO2000015264A1 In situ injection of antigen-presenting cells with genetically enhanced cytokine expression
03/23/2000WO2000015263A1 Expandible microparticle intracellular delivery system
03/23/2000WO2000015259A1 Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells
03/23/2000WO2000015258A1 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
03/23/2000WO2000015249A1 Treatment of kaposi's sarcoma with il-12
03/23/2000WO2000015247A2 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
03/23/2000WO2000015246A2 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
03/23/2000WO2000015244A2 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
03/23/2000WO2000015242A1 REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES
03/23/2000WO2000015235A1 Method of using tetracycline compounds to enhance interleukin-10 production
03/23/2000WO2000015231A1 Adenosine a3 receptor modulators
03/23/2000WO2000015228A1 Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents
03/23/2000WO2000015209A2 REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES
03/23/2000WO2000015208A2 New use of immunosupressants for mmp-mediated diseases
03/23/2000WO2000015206A2 Tryptophanyl ester and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes
03/23/2000WO2000015203A2 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
03/23/2000WO2000015198A1 Orally administered controlled drug delivery system providing temporal and spatial control
03/23/2000WO2000015176A2 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
03/23/2000WO2000015175A2 Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells
03/23/2000WO2000006134A3 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
03/23/2000WO2000003244A9 Immortalized human keratinocyte cell line
03/23/2000WO2000000599A3 Composition for the induction of apoptosis in target cells
03/23/2000WO1999067359A3 Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes and hybriomas and monoclonal antibodies therefore
03/23/2000WO1999065493A9 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
03/23/2000WO1999061418A3 1α-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF
03/23/2000WO1999061085A3 Method and compositions for treatment of cancers
03/23/2000WO1999056773A9 Composition comprising tumor cells and extracts and method of using thereof
03/23/2000WO1999053061A3 Tumor associated nucleic acids and uses therefor
03/23/2000WO1996040039A3 Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
03/23/2000DE19843489A1 New benzoylguanidine derivatives are Na+/H+ exchange inhibitors, useful for treatment of ischemia and other circulation disorders, tumors, prostatic hypertrophy and diabetic complications
03/23/2000DE19842415A1 Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
03/23/2000DE19816732A1 Diagnostik und Therapie von Erkrankungen im Zusammenhang mit HHV-8-Infektionen Diagnosis and treatment of diseases associated with HHV-8 infection
03/23/2000CA2344654A1 Regulation of her2/neu oncogene expression by synthetic polyamines
03/23/2000CA2344441A1 Expandible microparticle intracellular delivery system
03/23/2000CA2344316A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
03/23/2000CA2344151A1 Pharmaceutical preparation
03/23/2000CA2343838A1 Atp synthase subunit homolog
03/23/2000CA2343760A1 Orally administered controlled drug delivery system providing temporal and spatial control
03/23/2000CA2343578A1 Human serine/threonine protein kinases
03/23/2000CA2343355A1 In situ injection of antigen-presenting cells with genetically enhanced cytokine expression
03/23/2000CA2343354A1 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
03/23/2000CA2343313A1 A method of producing a functional immunoglobulin superfamily protein
03/23/2000CA2343220A1 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
03/23/2000CA2343133A1 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
03/23/2000CA2343001A1 Stomach polypeptide zsig28
03/23/2000CA2342833A1 Human gpcr proteins
03/23/2000CA2342601A1 Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells
03/23/2000CA2342395A1 Process for producing peptides from biological fluids and peptides obtainable by said process
03/23/2000CA2342301A1 Human cell junction pdz protein
03/23/2000CA2342292A1 Condensed plasmid-liposome complex for transfection
03/23/2000CA2342278A1 Inhibition of oncogene transcription by synthetic polyamides
03/23/2000CA2341683A1 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
03/23/2000CA2341440A1 Novel compounds
03/23/2000CA2341155A1 Genes encoding for the human and murine death inducer-obliterator-1
03/22/2000EP0987917A1 Method of cell data transmission, cell, communication system and corresponding network terminal unit
03/22/2000EP0987275A2 Molecules that home to a selected organ or tissue in vivo and methods of identifying same
03/22/2000EP0987263A2 Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
03/22/2000EP0987256A1 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid
1 ... 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 ... 2211